The modern treatment of heart failure is characterized by early intervention, multidimensional care and extended therapy options. Around half of all heart failure patients have a reduced left ventricular ejection fraction. With regard to drug therapy, according to ESC guidelines, there are four standard recommended drug classes that should be used early in HFrEF, as they are particularly important for reducing morbidity and mortality. SGLT-2 inhibitors are now recommended for HFrEF, HFmrEF and HFpEF.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Hepatitis B prophylaxis
Vaccination protection for healthcare staff with patient contact – an update
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Adrenogenital syndrome
Clinical care from birth to adulthood
- New approvals, current study data and ADC development
Antibody-drug conjugates in gynecologic oncology
- Type 2 diabetes: cardiovascular risk reduction is realistic
Modern active ingredients and lifestyle – every step counts
- From symptom to diagnosis
Pneumology – Covid-19: a review
- Irritable Bowel Syndrome
Functional disorder of gut-brain interaction – a biopsychosocial concept
- Abdominal aortic aneurysms in primary care